Liquidia Corporation (LQDA) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Liquidia Corporation (LQDA) closed at USD 33.94 on 2026-10-14, a change of +46.6 % over the past year, with a market capitalization of USD 3.11B.

Liquidia Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Liquidia Corporation key figures

Previous close

USD 33.94 (2026-10-14)

1-year change

+46.6 %

Market cap

USD 3.11B

Enterprise value

USD 3.01B

P/E ratio (trailing)

19.32

P/E ratio (forward)

15.90

EPS (trailing)

1.80

EPS (forward)

2.19

PEG ratio

n/a

Price to book

15.88

Revenue growth

1,842.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.68

Employees

216

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Liquidia Corporation

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Liquidia Corporation and compare it with other stocks.